Osteoporosis in men: An Endocrine Society clinical practice guideline

Nelson B. Watts, Robert A. Adler, John P. Bilezikian, Matthew M Drake, Richard Eastell, Eric S. Orwoll, Joel S. Finkelstein

Research output: Contribution to journalArticle

260 Citations (Scopus)

Abstract

Objective: The aim was to formulate practice guidelines for management of osteoporosis in men. Evidence: We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and evidence quality. Consensus Process: Consensus was guided by systematic evidence reviews, one in-person meeting, and multiple conference calls and e-mails. Task Force drafts were reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee; representatives of ASBMR, ECTS, ESE, ISCD; and members at large. At each stage, the Task Force received written comments and incorporated needed changes. The reviewed document was approved by The Endocrine Society Council before submission for peer review. Conclusions: Osteoporosis in men causes significant morbidity and mortality. We recommend testing higher risk men [aged ≥70 and men aged 50-69 who have risk factors (e.g. low body weight, prior fracture as an adult, smoking, etc.)] using central dual-energy x-ray absorptiometry. Laboratory testing should be done to detect contributing causes. Adequate calcium and vitamin D and weight-bearing exercise should be encouraged; smoking and excessive alcohol should be avoided. Pharmacological treatment is recommended for men aged 50 or older who have had spine or hip fractures, those with T-scores of -2.5 or below, and men at high risk of fracture based on low bone mineral density and/or clinical risk factors. Treatment should be monitored with serial dual-energy x-ray absorptiometry testing.

Original languageEnglish (US)
Pages (from-to)1802-1822
Number of pages21
JournalJournal of Clinical Endocrinology and Metabolism
Volume97
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Practice Guidelines
Osteoporosis
Testing
Bearings (structural)
Advisory Committees
Teleconferencing
X rays
Consensus
Smoking
X-Rays
Vitamin D
Minerals
Bone
Peer Review
Practice Management
Alcohols
Hip Fractures
Weight-Bearing
Postal Service
Calcium

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. M., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012). Osteoporosis in men: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 97(6), 1802-1822. https://doi.org/10.1210/jc.2011-3045

Osteoporosis in men : An Endocrine Society clinical practice guideline. / Watts, Nelson B.; Adler, Robert A.; Bilezikian, John P.; Drake, Matthew M; Eastell, Richard; Orwoll, Eric S.; Finkelstein, Joel S.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 97, No. 6, 06.2012, p. 1802-1822.

Research output: Contribution to journalArticle

Watts, NB, Adler, RA, Bilezikian, JP, Drake, MM, Eastell, R, Orwoll, ES & Finkelstein, JS 2012, 'Osteoporosis in men: An Endocrine Society clinical practice guideline', Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 6, pp. 1802-1822. https://doi.org/10.1210/jc.2011-3045
Watts, Nelson B. ; Adler, Robert A. ; Bilezikian, John P. ; Drake, Matthew M ; Eastell, Richard ; Orwoll, Eric S. ; Finkelstein, Joel S. / Osteoporosis in men : An Endocrine Society clinical practice guideline. In: Journal of Clinical Endocrinology and Metabolism. 2012 ; Vol. 97, No. 6. pp. 1802-1822.
@article{6b89cef4889345d4a53a7e81e23c5a37,
title = "Osteoporosis in men: An Endocrine Society clinical practice guideline",
abstract = "Objective: The aim was to formulate practice guidelines for management of osteoporosis in men. Evidence: We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and evidence quality. Consensus Process: Consensus was guided by systematic evidence reviews, one in-person meeting, and multiple conference calls and e-mails. Task Force drafts were reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee; representatives of ASBMR, ECTS, ESE, ISCD; and members at large. At each stage, the Task Force received written comments and incorporated needed changes. The reviewed document was approved by The Endocrine Society Council before submission for peer review. Conclusions: Osteoporosis in men causes significant morbidity and mortality. We recommend testing higher risk men [aged ≥70 and men aged 50-69 who have risk factors (e.g. low body weight, prior fracture as an adult, smoking, etc.)] using central dual-energy x-ray absorptiometry. Laboratory testing should be done to detect contributing causes. Adequate calcium and vitamin D and weight-bearing exercise should be encouraged; smoking and excessive alcohol should be avoided. Pharmacological treatment is recommended for men aged 50 or older who have had spine or hip fractures, those with T-scores of -2.5 or below, and men at high risk of fracture based on low bone mineral density and/or clinical risk factors. Treatment should be monitored with serial dual-energy x-ray absorptiometry testing.",
author = "Watts, {Nelson B.} and Adler, {Robert A.} and Bilezikian, {John P.} and Drake, {Matthew M} and Richard Eastell and Orwoll, {Eric S.} and Finkelstein, {Joel S.}",
year = "2012",
month = "6",
doi = "10.1210/jc.2011-3045",
language = "English (US)",
volume = "97",
pages = "1802--1822",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Osteoporosis in men

T2 - An Endocrine Society clinical practice guideline

AU - Watts, Nelson B.

AU - Adler, Robert A.

AU - Bilezikian, John P.

AU - Drake, Matthew M

AU - Eastell, Richard

AU - Orwoll, Eric S.

AU - Finkelstein, Joel S.

PY - 2012/6

Y1 - 2012/6

N2 - Objective: The aim was to formulate practice guidelines for management of osteoporosis in men. Evidence: We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and evidence quality. Consensus Process: Consensus was guided by systematic evidence reviews, one in-person meeting, and multiple conference calls and e-mails. Task Force drafts were reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee; representatives of ASBMR, ECTS, ESE, ISCD; and members at large. At each stage, the Task Force received written comments and incorporated needed changes. The reviewed document was approved by The Endocrine Society Council before submission for peer review. Conclusions: Osteoporosis in men causes significant morbidity and mortality. We recommend testing higher risk men [aged ≥70 and men aged 50-69 who have risk factors (e.g. low body weight, prior fracture as an adult, smoking, etc.)] using central dual-energy x-ray absorptiometry. Laboratory testing should be done to detect contributing causes. Adequate calcium and vitamin D and weight-bearing exercise should be encouraged; smoking and excessive alcohol should be avoided. Pharmacological treatment is recommended for men aged 50 or older who have had spine or hip fractures, those with T-scores of -2.5 or below, and men at high risk of fracture based on low bone mineral density and/or clinical risk factors. Treatment should be monitored with serial dual-energy x-ray absorptiometry testing.

AB - Objective: The aim was to formulate practice guidelines for management of osteoporosis in men. Evidence: We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and evidence quality. Consensus Process: Consensus was guided by systematic evidence reviews, one in-person meeting, and multiple conference calls and e-mails. Task Force drafts were reviewed successively by The Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee; representatives of ASBMR, ECTS, ESE, ISCD; and members at large. At each stage, the Task Force received written comments and incorporated needed changes. The reviewed document was approved by The Endocrine Society Council before submission for peer review. Conclusions: Osteoporosis in men causes significant morbidity and mortality. We recommend testing higher risk men [aged ≥70 and men aged 50-69 who have risk factors (e.g. low body weight, prior fracture as an adult, smoking, etc.)] using central dual-energy x-ray absorptiometry. Laboratory testing should be done to detect contributing causes. Adequate calcium and vitamin D and weight-bearing exercise should be encouraged; smoking and excessive alcohol should be avoided. Pharmacological treatment is recommended for men aged 50 or older who have had spine or hip fractures, those with T-scores of -2.5 or below, and men at high risk of fracture based on low bone mineral density and/or clinical risk factors. Treatment should be monitored with serial dual-energy x-ray absorptiometry testing.

UR - http://www.scopus.com/inward/record.url?scp=84861973260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861973260&partnerID=8YFLogxK

U2 - 10.1210/jc.2011-3045

DO - 10.1210/jc.2011-3045

M3 - Article

C2 - 22675062

AN - SCOPUS:84861973260

VL - 97

SP - 1802

EP - 1822

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -